Compugen gets Japanese patent for COM701, anti-PVRIG antibodies

Aug. 24, 2022 7:42 AM ETCompugen Ltd. (CGEN)By: Ravikash, SA News Editor

IP, Intellectual Property Patent Concept

Olivier Le Moal

  • Compugen (NASDAQ:CGEN) said that the Japan Patent Office granted a new composition of matter and use patent covering its anti-PVRIG, COM701 and backup anti-PVRIG antibodies.
  • The Japanese patent No. 2017-562952 is expected to expire not before 2036.
  • The company noted that in pre-clinical studies, blockade of PVRIG — a novel immune checkpoint — by COM701 has shown potent, reproducible enhancement of T cell activation, consistent with the desired mechanism of action of activating T cells in the tumor microenvironment to generate anti-tumor immune responses.
  • CGEN +1.57% to $1.29 premarket Aug. 24

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.